Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
EQS-News: Formycon publishes nine-month results for 2023
EQS-News: Formycon publishes nine-month results for 2023
EQS-News: Formycon publishes nine-month results for 2023
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting


Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients

EQS-Adhoc: Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements
EQS-Adhoc: Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements
EQS-Adhoc: Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
EQS-News: Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
EQS-News: Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
Savara Reports Third Quarter Financial Results and Provides Business Update: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Reports Third Quarter Financial Results and Provides Business Update


Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Inogen to Present at Upcoming Investor Conferences in November 2023: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen to Present at Upcoming Investor Conferences in November 2023


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following

Acadia Healthcare to Participate in November Conferences: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Participate in November Conferences


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in two conferences in November.



On Tuesday, November 14, 2023, the Company will participate in

LivaNova to Present at the Piper Sandler Healthcare Conference: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present at the Piper Sandler Healthcare Conference


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at

Humana Healthy Horizons partners with the Alzheimer’s Association to educate and support Floridians: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Healthy Horizons partners with the Alzheimer’s Association to educate and support Floridians


Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), is forging a path to better outcomes for those impacted by Alzheimer’s Disease and

Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023


Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and

NanoString to Webcast Presentations from Upcoming Healthcare Conferences: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString to Webcast Presentations from Upcoming Healthcare Conferences


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast

Almirall’s Nine-month 2023 Results:: https://mms.businesswire.com/media/20221109006035/en/1631769/5/ALM_AW_LOGO_Tagline_MV_Positive_RGB_%281%29.jpg
Almirall’s Nine-month 2023 Results:


Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.


Financial highlights (€ rounded million)


 


9M 2023


9M 2022

Savara to Present at the Jefferies London Healthcare Conference: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara to Present at the Jefferies London Healthcare Conference


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2023


Regulatory News:



POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Vistagen to Present at Stifel 2023 Healthcare Conference: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at Stifel 2023 Healthcare Conference


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

ISoP New Board of Trustees Members Announced: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
ISoP New Board of Trustees Members Announced


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced today that Amparo de la Peña, Vice

Silence Therapeutics to Present at Jefferies London Healthcare Conference: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg
Silence Therapeutics to Present at Jefferies London Healthcare Conference


Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through

Charles River Laboratories Announces Third-Quarter 2023 Results: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Announces Third-Quarter 2023 Results


Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 3.8% from $989.2

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
ICON plc to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON plc to Present at Upcoming Investor Conferences


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the Jefferies

Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2


DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today new market research which found 79% of people struggle to

Xencor Reports Third Quarter 2023 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Reports Third Quarter 2023 Financial Results


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today